Switch theme
Sign up to access all valuation multiples
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
2001
24
LTM Revenue $6K
LTM EBITDA -$24.0M
$62.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genelux has a last 12-month revenue of $6K and a last 12-month EBITDA of -$24.0M.
In the most recent fiscal year, Genelux achieved revenue of $8K and an EBITDA of -$29.0M.
Genelux expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genelux valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.2M | $8K | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$26.5M | -$29.0M | XXX | XXX | XXX |
| EBITDA Margin | -15563% | -362075% | XXX | XXX | XXX |
| Net Profit | -$5.2M | -$28.3M | XXX | XXX | XXX |
| Net Margin | -3063% | -353712% | XXX | XXX | XXX |
| Net Debt | $24.5M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Genelux's stock price is $2.
Genelux has current market cap of $91.0M, and EV of $62.0M.
See Genelux trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $62.0M | $91.0M | XXX | XXX | XXX | XXX | $-0.97 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Genelux has market cap of $91.0M and EV of $62.0M.
Genelux's trades at 10875.5x LTM EV/Revenue multiple, and -2.6x LTM EBITDA.
Analysts estimate Genelux's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Genelux and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $62.0M | XXX | XXX | XXX |
| EV/Revenue | 7746.9x | XXX | XXX | XXX |
| EV/EBITDA | -2.1x | XXX | XXX | XXX |
| P/E | -3.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGenelux's NTM/LTM revenue growth is -100%
Genelux's revenue per employee for the last fiscal year averaged $0K, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Genelux's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Genelux's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Genelux and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -95% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -362075% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 158825% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 237475% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 396300% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genelux acquired XXX companies to date.
Last acquisition by Genelux was XXXXXXXX, XXXXX XXXXX XXXXXX . Genelux acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Genelux founded? | Genelux was founded in 2001. |
| Where is Genelux headquartered? | Genelux is headquartered in United States of America. |
| How many employees does Genelux have? | As of today, Genelux has 24 employees. |
| Who is the CEO of Genelux? | Genelux's CEO is Mr. Thomas Zindrick, J.D.. |
| Is Genelux publicy listed? | Yes, Genelux is a public company listed on NAS. |
| What is the stock symbol of Genelux? | Genelux trades under GNLX ticker. |
| When did Genelux go public? | Genelux went public in 2023. |
| Who are competitors of Genelux? | Similar companies to Genelux include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Genelux? | Genelux's current market cap is $91.0M |
| What is the current revenue of Genelux? | Genelux's last 12-month revenue is $6K. |
| What is the current EBITDA of Genelux? | Genelux's last 12-month EBITDA is -$24.0M. |
| What is the current EV/Revenue multiple of Genelux? | Current revenue multiple of Genelux is 10875.5x. |
| What is the current EV/EBITDA multiple of Genelux? | Current EBITDA multiple of Genelux is -2.6x. |
| What is the current revenue growth of Genelux? | Genelux revenue growth between 2023 and 2024 was -95%. |
| Is Genelux profitable? | Yes, Genelux is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
